Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.